NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/07/2025
Voltar para busca
Dado oficial do USPTO
SLOREL
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
42
Atualização mais recente
08/07/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
15/09/2022
Data de registro
08/07/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
08/07/2025
Última transação
08/07/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
03
Localização do titular
Gyeonggi-do, KR
Examinador
SAXTON, EVELYN H
Unidade examinadora
M30
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
CG Bio Co., Ltd.
Representantes
Caroline E. Bryce SHERIDAN ROSS P.C.
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Surgical implants comprised of living tissues for guided tissue regeneration; implants comprising living tissue; implantable materials for use in guided tissue regeneration in the nature of implants comprising living tissue; Surgical implants comprised of living tissues used in transplantsvascular grafts being living tissue and human allograft tissue; surgical implants comprised of living tissues; human allograft tissue; bone void fillers comprised of living tissues; Stem cells for medical purposessurgical implants grown from stem cells; pharmaceutical preparations for use in tissue transplantation; pharmaceutical preparations for tissue regeneration; medicines for human purposespharmaceutical preparations for the treatment of musculo-skeletal disorders; medicines for human purposesa drug delivery system comprising liquidspowderstablets or capsules for the continuous release of a wide variety of therapeutic agentspharmaceutical preparations for the treatment of musculo-skeletal disorders; drugs for medical purposesdrugs for use in bioregenerative proceduresdrugs for use for regenerative purposedrugs for use to assist with artificial bone growthdrugs for use in accelerating bone formationdrugs for use to stimulate new bone formation; pharmaceutical agents affecting sensory organs; pharmaceutical preparations for the prevention of diseases of the musculo- skeletal system; pharmaceutical preparations for the treatment of Musculo-skeletal disorders; cellular function activating agents for medical purposes; pharmaceutical preparations for use in organ transplantation; biological tissue cultures for medical purposes; drug delivery agents in the form of liquidpowderstablets and capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of dissolvable films added to bone substitutes that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films for use in bioregenerative procedures that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films that provide sustained release of drugs for use with implants and bone substitutes that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of drug delivery compounds that facilitate sustained or extended release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of dissolvable films with controlled timing and rate of drug release that facilitate the delivery of pharmaceutical preparations; medicines for human usenamely pharmaceutical preparations for the treatment of musculo-skeletal disorders featuring controlled timing and rate of release; medical bone graft substitutebiological tissue bone grafts; medical bone graft materialsbone fillers consisting of living materials; medical bone graft materials with drug release function being bone growth media consisting of biological materials for medical bone graft purposes with drug release function; medical bone graft materialsbiological bone tissue intended for subsequent implantation in a bone graft with drug release functionthat provide sustained release of drugs for use with implants and bone substitutes; medical bone graft materials being biological bone tissue intended for subsequent implantation with drug release function that are sold filled with pharmaceutical preparationsbiological growth factorsused with implants and bone substitutes; medical bone graft materials being biological bone tissue intended for subsequent implantation with drug release function that are sold filled with pharmaceutical preparationsantibioticsused with implants and bone substitutes
Publicações
Histórico de despachos e eventos da marca no USPTO.
42 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
08/07/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
20/05/2025
PUBO
PUBLISHED FOR OPPOSITION
20/05/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
14/05/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/04/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/03/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/03/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/03/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/01/2025
GNRT
NON-FINAL ACTION E-MAILED
08/01/2025
CNRT
NON-FINAL ACTION WRITTEN
08/01/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
17/12/2024
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
12/12/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/12/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/12/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/12/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/11/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/11/2024
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
06/11/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/11/2024
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
06/11/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/11/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/11/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/11/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/11/2024
ALIE
ASSIGNED TO LIE
05/11/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
13/08/2024
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
12/03/2024
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
17/01/2024
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
16/06/2023
GNSL
LETTER OF SUSPENSION E-MAILED
16/06/2023
CNSL
SUSPENSION LETTER WRITTEN
16/06/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/05/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/05/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/05/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
14/04/2023
GNRT
NON-FINAL ACTION E-MAILED
14/04/2023
CNRT
NON-FINAL ACTION WRITTEN
14/04/2023
DOCK
ASSIGNED TO EXAMINER
14/03/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/10/2022
NWAP
NEW APPLICATION ENTERED
19/09/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SLOREL ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.